Chronic Myelomonocytic Leukemia: Focus on Clinical Practice

Area of Science:

• Hematology
• Oncology
• Stem Cell Biology

Background:

• Chronic myelomonocytic leukemia (CMML) is a clonal stem cell disorder.
• It shares features with myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs).
• CMML often leads to peripheral blood monocytosis and can transform into acute myeloid leukemia.

Purpose of the Study:

• To review the current understanding of CMML, including its molecular landscape and prognostic factors.
• To discuss current management strategies and their limitations.
• To highlight the need for novel therapeutic approaches and CMML-specific response criteria.

Main Methods:

• Review of existing literature on CMML.
• Analysis of common genetic mutations (TET2, SRSF2, ASXL1, RAS) and their prognostic implications.
• Evaluation of current treatment paradigms extrapolated from MDS and MPN.

Main Results:

• Over 90% of CMML patients have molecular abnormalities, with TET2, SRSF2, ASXL1, and RAS being frequent.
• ASXL1 mutations (nonsense, frameshift) are linked to poorer overall survival.
• Current treatments (hydroxyurea, hypomethylating agents) show limited efficacy, and allogeneic stem cell transplant carries risks.

Conclusions:

• There is a critical need for CMML-specific treatment and response criteria.
• Novel drugs targeting molecular and epigenetic abnormalities are under development.
• Improved understanding and targeted therapies are essential to enhance clinical outcomes for CMML patients.